The Netherlands Cancer Institute shared a post on LinkedIn:
“The largest published prospective evaluation of off-label targeted cancer therapies shows that more patients could benefit from existing drugs.
Published today in Nature, results from the Dutch multicenter DRUP trial include more than 1600 patients with advanced cancers who had no remaining standard treatment options.
The study shows that this strategy can offer substantial benefit, while also making clear that off-label targeted therapies should only be used within clinical trial settings where efficacy and toxicity are systematically evaluated.
By matching existing drugs to patients beyond their approved indications, the pan-cancer DRUP trial aims to expand personalized treatment options and build the evidence needed to improve access.
Read the full article here.
Image: Overview of tumor DNA changes based on whole-genome analysis, revealing potential treatment targets through mutations, deletions, amplifications, and structural variations.”
Other articles about DNA on OncoDaily.